Parkinson's Disease

The Parkinson's Disease pipeline: 119 tracked drugs, 17 approved for this indication.

17 approved / phase 414 Phase 32 Phase 2/334 Phase 211 Phase 1/233 Phase 11 US approval withdrawn7 preclinical / unstaged

Compare the share prices of listed companies in Parkinson's Disease →

Total attributable cost

$25.4B

$24,439/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities (2017 MEPS-anchored estimate) · US

The Parkinson's Disease pipeline

Key trial results for every approved and late-stage drug: Parkinson's Disease results by drug.

← all assets